Obesity as a cause of damage to the liver and the cardiovascular system. Mechanisms and management

1. World Health Organization. Obesity: preventing and managing the global epidemic, 1997 (Электронный ресурс). URL: http://apps.who.int/iris/handle/10665/63854. Дата обращения: 06.03.2018. 2. Клинические рекомендации по лечению морбидного ожирения у взрослых. МЗ РФ, Российская ассоциация эндокринологов, Российское общество бариатрических хирургов. 2016 [Klinicheskie rekomendacii po lecheniyu morbidnogo ozhirenia u vzroslih MZ RF. Rossiyskaya assotsiatsiya endokrinologov, Rossiyskoye obshchestvo bariatricheskikh khirurgov. 2016 (in Russian)] (Электронный ресурс). URL: https://www.endocrincentr.ru/sites/default/files/specialists/science/clinic-recomendations/klin_rek_mo-_2016.pdf. Дата обращения: 06.03.2018. 3. Eur. Assoc. Study Liver, Eur. Assoc. Study Diabetes, Eur. Assoc. Study Obes. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease // J. Hepatol. 2016. Vol. 64. P. 1388–1402. 4. Vanni E., Marengo A., Mezzabotta L., Bugianesi E. Systemic complications of nonalcoholic fatty liver disease: when the liver is not an innocent bystander // Semin. Liver Dis. 2015. Vol. 35. P. 236–249. 5. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2016 году. Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2017. С. 36–37 [O sostoyanii sanitarno-epidemiologicheskogo blagopoluchia naselenia RF v 2016 godu: Gosudarstvenniy doklad. Federal’naya sluzhba po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka, 2017. S. 36–37 (in Russian)]. 6. Younossi Z. M., Koenig A. B., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease - meta-analytic assessment of prevalence, incidence, and outcomes // Hepatology. 2016. Vol. 64. P. 73–84. 7. Драпкина О. М., Ивашкин В. Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (результаты открытого многоцентрового проспективного исследования-наблюдения DIREGL 01903) // Рос. журн. гастроэнтерол. гепатол., колопроктол. 2014. Т. 24. № 4. С. 32–38 [Drapkina O.M., Ivashkin V. T. Epidemiologicheskie osobennosty nealkogolnoy zhirovoy bolezny pecheny v Rossii (rezul’taty otkrytogo mnogotsentrovogo prospektivnogo issledovaniya-nablyudeniya DIREGL 01903) // Ros. J gastroenterol gepatol koloproktol. 2014. Т. 24. № 4. S. 32–38 (in Russian)]. 8. Аметов А. С., Демидова Т. Ю., Целиковская А. Л. Ожирение и сердечно-сосудистые заболевания // Тер. Архив. 2001. № 8. C. 69–72 [Ametov A.S., Demidova T. Y., Celikovskaya A. L. Ozhirenie i serdechno-sosudistie zabolevanya // Ter. Arhiv. 2001. № 8. S. 69–72 (in Russian)]. 9. Диагностика и лечение неалкогольной жировой болезни печени / под ред. акад. РАН, профессора В. Т. Ивашкина. М., 2015. 32 c. [Diagnostika i lechenie nealkogolnoi zhirovoi bolezni pecheny / pod red. akad. RAN, prof. V. T. Ivashkina. M., 2015. 32 s. (in Russian)]. 10. Arab J. P., Karpen S. J., Dawson P. A. et al. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives // Hepatology. 2017. Vol. 65. P. 350–362. 11. Zomer E., Gurusamy K., Leach R. et al. Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis // Obes Rev. 2016. Vol. 17 (10). P. 1001–1011. 12. Chalasani N., Younossi Z., Lavine J. E. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association // Hepatology. 2012. Vol. 55. P. 2005–2023. 13. Sung K. C., Ryu S., Lee J. Y. et al. Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver // J. Hepatol. 2016. Vol. 65. P. 791–797. 14. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group // Lancet. 1998. Vol. 352. P. 854–865. 15. Johnson J. A., Simpson S. H., Toth E. L., Majumdar S. R. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes // Diabet Med. 2005. Vol. 22. P. 497–502. 16. Li Y., Liu L., Wang B. et al. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis // Biomed Rep. 2013. Vol. 1 (1). P. 57–64. 17. Staels B., Rubenstrunk A., Noel B. et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis // Hepatology. 2013. Vol. 58. P. 1941–1952. 18. Sanyal A. J., Chalasani N., Kowdley K. V. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis // N. Engl. J. Med. 2010. Vol. 362. P. 1675–1685. 19. Marso S.P., Daniels G. H., Brown-Frandsen K. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes // N Engl J Med. 2016. Vol. 375 (4). P. 31–322. 20. Armstrong M. J., Gaunt P., Aithal G. P. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebocontrolled phase 2 study // Lancet. 2016. Vol. 387. P. 679–690. 21. Blaslov K., Bulum T., Zibar K., Duvnjak L. Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease // World J Gastroenterol. 2014. Vol. 20. P. 7356–7365. 22. Balaban Y. H., Korkusuz P., Simsek H. et al. Dipeptidyl peptidase IV (DDP IV) in NASH patients // Ann Hepatol. 2007. Vol. 6. P. 242–250. 23. Iwasaki T., Yoneda M., Inamori M. et al. Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus // Hepatogastroenterology. 2011. Vol. 58. P. 2103–2105. 24. Wong V. W., Chitturi S., Wong G. L. et al. Pathogenesis and novel treatment options for non-alcoholic steatohepatitis // Lancet Gastroenterol. Hepatol. 2016. Vol. 1. P. 56–67. 25. Athyros V.G,. Katsiki N., Karagiannis A., Mikhailidis D. P. Statins and non-alcoholic steatohepatitis // J. Hepatol. 2016. Vol. 64. P. 241–242. 26. Argo C. K., Patrie J. T., Lackner C. et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial // J. Hepatol. 2015. Vol. 62. P. 190–197. 27. Gonciarz Z., Besser P., Lelek E. et al. Randomised placebo-controlled double-blind trial on “essential phospholipids in the treatment of fatty liver associated with diabetes // Med. Chir. Digest. 1988. Vol. 17 (1). P. 61–65. 28. Sas E., Grinevich V., Efimov O. et al. Beneficial influence of polyunsaturated Phosphatidylcholine enhances functional liver condition and liver structure in patients with Nonalcoholic steatohepatitis. Results of prolonged randomized blinded prospective clinical study // Journal of Hepatology. 2013. Vol. 58 (Suppl. 1). P. 549. 29. Dajani A. I., Abu Hammour A. M., Zakaria M. A. et al. EPL in the management of primary NAFLD and NAFLD associated with comorbid disease // Arab J Gastroenterol. 2015. Vol. 16 (3–4). P. 99–104. 30. Sun C., Zheng X., Tan Z. et al. Clinical Observation on Polyene Phosphatidyl Choline and Metformin in the Treatment of Type 2 Diabetes and Non-alcoholic Fatty Liver Disease // Clinical Focus. 2008. Vol. 23 (17). P. 1272–1273. 31. Yin D., Kong L. Observation for curative effect of Essentiale in treatment of fatty liver caused by diabetes mellitus // Med. J. Q. 2000. Vol. 15. P. 277–278. 32. Сас Е. И., Блинов Д. В., Зимовина У. В. и др. Xарактеристика пациентов, получающих лечение эссенциальными фосфолипидами в условиях реальной клинической практики // Клинические перспективы гастроэнтерологии, гепатологии. 2015. № 1. С. 9–17 [Sas Ye.I., Blinov D. V., Zimovina U. V. i dr. Xarakteristika patsiyentov, poluchayushchikh lecheniye essentsial’nymi fosfolipidami v usloviyakh real’noy klinicheskoy praktiki // Klinicheskiye perspektivy gastroenterologii, gepatologii. 2015. № 1. S. 9–17 (in Russian)]. 33. Sas E., Grinevich V., Efimov O. et al. Beneficial influence of polyunsaturated Phosphatidylcholine enhances functional liver condition and liver structure in patients with Nonalcoholic steatohepatitis. Results of prolonged randomized blinded prospective clinical study // Journal of Hepatology. 2013. Vol. 58. P. 549. 34. Sun C., Zheng X., Tan Z. et al. Clinical observation on polyene phosphatidyl choline and metformin in the treatment of type 2 diabetes and non-alcoholic fatty liver disease // Clin Focus. 2008. Vol. 23(17). P. 1272–1273 (in Chinese). 35. Xiang Z., Chen Y., Ma K. et al. The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review // BMC Gastroenterol. 2013. Vol. 13. P. 140. 36. Loomba R., Lawitz E., Mantry P. S. et al. GS-4997, an inhibitor of apoptosis signal-regulating kinase (ASK1), alone or in combination with simtuzumab for the treatment of nonalcoholic steatohepatitis (NASH): a randomized, phase 2 trial // Hepatology. 2016. Vol. 64. P. 1119A. 37. Anstee Q. M., Concas D., Kudo H. et al. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis // J. Hepatol. 2010. Vol. 53. P. 542–550.